Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.

@article{Koskinas2018DesignOT,
  title={Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.},
  author={Konstantinos C. Koskinas and Stephan Windecker and Aliki Buhayer and Baris Gencer and Giovanni Battista Pedrazzini and Christian Mueller and St{\'e}phan Cook and Olivier Muller and Christian M Matter and Lorenz R{\"a}ber and Dik Heg and François Mach},
  journal={Clinical cardiology},
  year={2018},
  volume={41 12},
  pages={
          1513-1520
        }
}
Statins lower low-density lipoprotein cholesterol (LDL-C) and improve clinical outcomes in patients with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) often do not achieve LDL-C targets despite potent statin treatment, and have a particularly high risk of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic subjects… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

François Mach, Colin Baigent, +18 authors Olov Wiklund
  • European heart journal
  • 2019
VIEW 1 EXCERPT
CITES METHODS

Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation

  • Oxidative medicine and cellular longevity
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND